Compare Tesla, Inc. (TSLA) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tesla, Inc. vs GeneDx Holdings Corp — how do they compare? Tesla, Inc. trades at $383.64 (market cap $1.48T), while GeneDx Holdings Corp trades at $67.75 (market cap $2.02B). The key difference: Tesla, Inc. is far larger — about 732.7× GeneDx Holdings Corp's market cap, and Tesla, Inc. is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tesla, Inc. for 88 Days and GeneDx Holdings Corp for 19 Days on average.
| TSLA | WGS | |
|---|---|---|
Market Cap | $1.48T | $2.02B |
Volume | 28,215,427 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $489.88 | $167.51 |
52-Week Low | $298.16 | $34.51 |
Typical Hold Time | 88 Days | 19 Days |
Enterprise Value | $1.45T | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tesla trades at $382.89, up 1.4% with a bullish technical signal from moving averages. The company shows mixed fundamentals with declining profit margins (3.67% net income margin) despite recent earnings beats, while valuation ratios remain elevated (P/E 347). Recent news highlights regulatory approval for driver-assistance software in Europe and a potential cheaper EV model, though Q2 2026 earnings missed expectations. Cash flow trends show consistent operational strength but heavy investment outflows.
Tesla's outlook balances innovation leadership in autonomy and energy against near-term execution risks and rich valuations. The consensus price target of $441 suggests 15% upside, but investors face volatility from competitive pressures and reliance on future technology adoption. The stock's performance hinges on delivering growth beyond traditional automotive segments.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
